AN APPROACH TO ENHANCE THE SOLUBILITY OF RIFAPENTINE BY SOLID DISPERSION TECHNIQUE USING HYDROPHILIC CARRIERS by Pathak, Vinay Madhav et al.
Vinay et al                                          Journal of Drug Delivery & Therapeutics; 2013, 3(4), 8-14                                8 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
Available online at http://jddtonline.info 
RESEARCH ARTICLE 
AN APPROACH TO ENHANCE THE SOLUBILITY OF RIFAPENTINE BY SOLID 
DISPERSION TECHNIQUE USING HYDROPHILIC CARRIERS 
*Pathak Vinay Madhav
1
, Rawat Swati
1
, Sharma Y.P.
1
, Priyanshu Jain
2, 
Sagar B Thoke
1
 
1Department of Pharmaceutics, S.N.D. College of Pharmacy, Babhulgaon, Yeola, Nashik, India 
2Department of Pharmaceutical Chemistry, S.N.D. College of Pharmacy, Babhulgaon, Yeola, Nashik, India 
*Corresponding Author’s E mail: realpharmaworld@gmail.com, vinay.mp.pathak@gmail.com, Contact no.: 9403466286, 9657945056 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Rifapentine is a semisynthetic rifamycin derivative from 
the piperazinyl hydrazone class with a microbiologic 
profile similar to that of rifampin.
1  
Its structure differs 
from that of rifampin by the presence of a cyclopentyl ring 
instead of a methyl group at the piperazinyl moiety.
2
  The 
chemical formula of rifapentine is rifamycin, 3-[[(4-
cyclopentyl- 1-piperazinyl)imino] methyl]. Its molecular 
formula is C47H64N4O and its molecular weight is 
approximately 877 Da.
3
 
 
Fig. 1 Structure of Rifapentine
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Rifapentine was first synthesized in 1965 by the same 
company that produced rifampin. The drug was approved 
by the Food and Drug Administration (FDA) in June 1998. 
It is synthesized in one step from rifampicine.
5
Rifapentine 
is approved for the treatment of tuberculosis in the US. 
The drug is also used in China. Rifapentine has a long 
half-life which allows for once-weekly administration. 
When administered twice weekly during the intensive 
phase and once weekly during the continuation phase, 
rifapentine has demonstrated efficacy in the treatment of 
pulmonary tuberculosis in immunocompetent patients.
6
 
Rifapentine has a potential advantage over rifampcin 
because its long half-life (13 hours compared with 3 hours) 
could allow for less frequent dosing. Aqueous solubility of 
any therapeutically active substance is a key property as it 
governs dissolution, absorption and thus the efficacy in 
vivo. Currently only 8% of new drug candidates have both 
high solubility and permeability. Solubilization of poorly 
aqueous soluble drug forms an important activity in 
formulation process. For many formulation scientists in the 
big pharma companies, it became clear in the early 1990s 
that they had to learn and invest much more into 
solubilizing/enhancing technologies like complexation of 
drug candidates with cyclodextrins, microemulsion 
(SMEDDS formulations), nanosuspension or solid 
dispersion formulation technologies having the potential to 
enhance bioavailability.
7 
This study seeks to investigate 
kneading method, physical mixture, and solvent 
evaporation as a method for the preparation of these binary 
systems as well as their solid state characterization by 
employing analytical tools such as Fourier Transform 
infrared (FTIR), Powder X-ray Diffraction (XRD), 
Differential Scanning Calorimetry (DSC), particle size 
analysis and Scanning electron microscopy (SEM). 
MATERIAL AND METHODS 
Rifapentine was obtained from Lupin Pharmaceuticals, 
Aurangabaad, as a gift sample. PVP-K30, HPMC and 
methanol were purchased from S.D.fine chemicals limited, 
Mumbai. All the carriers used were of analytical grade. 
Methods 
8-10
  
The Preparation of drug-PVP-K30 and drug-HPMC solid 
dispersions were prepared by kneeding and solvent 
evaporation Techniques which are described below: (Table 
1)  
Abstract 
The aim of this present work was to improve the dissolution profile of Rifapentine (RPT) using solid dispersions technique 
with PVP K-30 or HPMC as the carrier, in different ratios of 1:1, 1:2, 1:3, 1:4, 1:5 by the kneading method and solvent 
evaporation method. For the purpose of comparison, another formulation was prepared by the method of physical mixture 
with the drug and carrier weight ratios of same. The prepared solid dispersions (SDs) were optimized on the basis of 
evaluation of Solubility, percentage drug release rate and percentage drug content. Optimized formulation is then 
characterized by Fourier Transform Infrared Spectroscopy (FTIR), Powder X-ray Diffraction (XRD), Differential Scanning 
Calorimetry (DSC), Particle size analysis and Scanning Electron Microscopy (SEM) in order to ascertain any physicochemical 
interactions between the drug and carrier that could affect the dissolution profile of the drug. The dissolution studies were 
conducted for pure Rifapentine and all the formulated solid dispersions. All the solid dispersions prepared by kneading 
method and solvent evaporation method showed an enhanced dissolution profile of Rifapentine, as compared to that of pure 
drug alone but among them all, the solid dispersion prepared with PVP-K30 by solvent evaporation method in 1:3 ratio 
showed better enhancement of solubility and dissolution rate. 
Keywords: Solid dispersion, Rifapentine, solvent evaporation method, Kneeding method, PVP K-30, HPMC. 
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Table 1: Formulation code of Solid Dispersion for different method of preparation 
Sr. No. Name of method Drug : polymer ratio 
Solid dispersions 
With PVP-K30 With HPMC 
1 Physical mixtures 1:1 PM1 PM2 
2 Kneeding method 
1:1 SP1 SH1 
1:2 SP2 SH2 
1:3 SP3 SH3 
1:4 SP4 SH4 
1:5 SP5 SH5 
3 Solvent evaporation method 
1:1 SP6 SH6 
1:2 SP7 SH7 
1:3 SP8 SH8 
1:4 SP9 SH9 
1:5 SP10 SH10 
 
Physical Mixture 
Physical mixtures were prepared by simple blending in a 
glass mortar of accurately weighed quantities of drug(s) 
and carrier(s) for about one hour in ratio of 1:1and passed 
through sieve no.85 and stored in desiccator over fused 
calcium chloride.  
Kneading Method 
Separate sets of mixture of HPMC-Rifapentine and PVP-
K30-Rifapentine were weighed accurately in specified 
quantity (1:1, 1:2, 1:3, 1:4 and 1:5). The mixtures were 
wetted with water: methanol (50% v/v) and kneaded 
thoroughly for 45 min in glass mortar. Further, the 
products was dried at 40
0
C for 48 hr, passed through sieve 
No.85 and stored in a desiccator over fused calcium 
chloride. 
Solvent-Evaporation method 
The Accurately weighed amount of Drug and HPMC (1:1, 
1:2, 1:3, 1:4 and 1:5) were dissolved in methanol to get a 
clear solution and same preparation for drug and PVP-K30 
ratios. The resulting solution was stirred at ambient 
temperature until complete evaporation of the solvent 
occurred. The resulting preparation were kept in 
desiccators for the least 48 hr and then grounded in a glass 
mortar for size reduction and passed through sieve no.85 
and stored in desiccators over fused calcium chloride. 
Characterization of solid dispersion 
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Drug Content Determination 
Powdered solid dispersion and physical mixture equivalent 
to 10 mg Rifapentine drug accurately weighed and 
transferred to 100 ml volumetric flask. About 20 ml water 
added and flask shaken gently to dissolve complete 
residue. Then make up volume with water which gives 
resulting solution of 100 μg/ml. 1 ml of resulting solution 
was taken in 10 ml volumetric flask and volume was make 
up with water. The absorbance of this solution was taken at 
476.5 nm in UV spectrophotometer. And drug content was 
determined. 
Solubility determination 
The apparent solubility of Rifapentine drug and solid 
dispersions were determined in distilled water at 37°C. 
Excess amount of Rifapentine solid dispersion was added 
to 10 ml of solvent in glass vials with rubber closers. Then 
the vials were kept on a shaker incubator maintained at 37 
± 0.5°C for 24 h. After shaking, the vials were kept in an 
incubator at 37 ± 0.5°C for equilibrium for 12 h. The 
solution was then filtered through whatman no.4 filter and 
the filtrate was assayed spectrophotometrically at 476.5 
nm. 
 In vitro Dissolution Studies 
An ELECTROLAB dissolution test apparatus USP Type II 
(Paddle) at rotation speed of 50 rpm was used for the 
study. Dissolution of the drug and samples was carried out 
on an equivalent of 600 mg of the Rifapentine, 0.1 N HCL 
was used as dissolution media. The volume and 
temperature of the dissolution media were 900 ml and 37 ± 
0.2 0C, respectively. After fixed time intervals, 5 ml of 
samples were withdrawn and sink condition was 
maintained. These samples were assayed through 
ultraviolet absorbance measurement at 478 nm using UV-
Visible Spectrophotometer (Chemito-2600) by an 
analytically validated method (r2 = 0.995 and y = 
0.005X+0.02). The samples were estimated for amount of 
Rifapentine dissolved by measuring their absorbance at 
478nm. Samples were taken at time interval of 5, 15, 30, 
45, 60, 75, 90 min.  
From the calculations the highest release showing solid 
dispersion was optimized.  
Infrared Spectroscopy 
IR spectra of drug as well as optimized solid dispersion 
were obtained using BRUKER FTIR. Drug and optimized 
solid dispersion were analyzed by IR spectral studies. In 
this method, the drug sample was scanned in the region of 
400-4000 cm-1. 
Particle Size Determination 
Particle size analyses of plain drug as well as optimized 
solid dispersion were carried out with MASTERSIZER 
2000 of Malvern. Sample was scanned for 0.1 to 3000µm 
size of particles. 
DSC analysis 
The DSC study was performed on a Mettler Toledo DSC 
822e differential scanning calorimeter with thermal 
analyzer. Accurately weighed sample (about 2 mg of 
sample) was placed in sealed aluminum pan, before 
heating under nitrogen flow (20 ml/min) at a scanning rate 
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of 10
0
C per min from 0 to 200
0
C. An empty aluminum pan 
was used as reference. 
X-ray Powder Diffraction (XRD) 
X-ray diffraction analysis was performed using Bruker 
AXS D8 Advanced model (high beam monochromatic) 
using Cu radiation which was generated at 40 Kv and 40 
mA at 1.540600A. The rate of the scanning was 0.30°C 
/min.  
Scanning Electron Microscopy (SEM) 
The samples, an appropriate amount of Rifapentine or 
Solid dispersion powder or a glass slide with a small drop 
of the suspension, were fixed on an SEM stub using 
double-sided adhesive tape and coated with Au at 50mA 
for 6min through a sputter-coater (KYKY SBC-12, 
Beijing, China). A scanning electron microscope with a 
secondary electron detector was used to obtain digital 
images of the samples at an accelerating voltage of 10 kV. 
RESULTS 
Standard graph 
Rifapentine was found to be soluble in 0.1N HCL. A 
simple reproducible method of estimation was carried out 
in 0.1N HCL ranging from 10-80 µg/ml solutions at 478 
nm (Table 2) against the blank the standard graph obtained 
was linear, with regression coefficient 0.997 and straight 
line equation y = 0.005x + 0.022. (Figure 2) 
 
Figure 2: Standard graph of Rifapentine in 0.1N HCL 
Table 2: Standard graph of Rifapentine 
Sr. No. Concentration(µg/ml) Absorbance 
1 10 0.071 
2 15 0.099 
3 20 0.113 
4 25 0.142 
5 30 0.171 
6 35 0.201 
7 40 0.218 
8 45 0.235 
9 50 0.276 
10 55 0.292 
11 60 0.311 
12 65 0.332 
13 70 0.368 
14 75 0.389 
15 80 0.415 
 
 
Figure 3: UV-visible absorption spectrum of Rifapentine in 0.1N HCL 
 
Table 3: Standard calibration curve of Rifapentine in 
distilled water 
Sr. No. Concentration(µg/ml) Absorbance 
1 10 0.078 
2 20 0.12 
3 30 0.173 
4 40 0.231 
5 50 0.282 
6 60 0.325 
7 70 0.373 
8 80 0.426 
 
Figure 4: Standard calibration curve of Rifapentine 
in distilled water
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Figure 5: UV-visible absorption spectrum of Rifapentine in water 
From the calibration curve equation is given as,  
Y=0.004X + 0.029 
The value of R
2 
is 0.998. On the basis of obtained results it was concluded that Rifapentine obeys Beer- Lambert,s law in 
the range of 10-80 ug/ml. 
Table 4: Aqueous solubility, % Drug Content and % In vitro release (90 min.) of prepared physical mixtures 
Sr. No. Batch code Aqueous solubility (mg/ml) % Drug content ± S.D. % In vitro release (90 min.) 
1 Plain drug 0.623±0.008 - 38.03±0.16 
2 PM1 0.841±0.002 86.41±0.05 49.84±0.21 
3 PM2 0.752±0.014 94.32±0.14 51.80±0.08 
 
Table 5: Aqueous solubility, % drug content and % vitro drug release (90 min.) of prepared solid dispersions 
Sr. 
No. 
Kneeding method Solvent evaporation method 
Batch 
code 
Aqueous 
solubility 
(mg/ml) 
% drug 
content ± 
S.D. 
% vitro drug 
release (90 
min.) 
Batch 
code 
Aqueous 
solubility 
(mg/ml) 
% drug 
content ± 
S.D. 
% vitro drug 
release (90 
min.) 
1 SP1 1.04±0.002 90.48±0.208 81.71 SP6 2.31±0.016 89.28±0.172 88.79 
2 SP2 1.71±0.004 86.26±0.046 84.86 SP7 3.24±0.003 92.54±0.027 91.15 
3 SP3 4.51±0.013 89.71±0.291 84.07 SP8 6.34±0.002 87.71±0.081 93.91 
4 SP4 2.86±0.017 94.81±0.163 88.79 SP9 5.47±0.015 94.83±0.401 90.36 
5 SP5 4.59±0.001 90.32±0.052 87.22 SP10 4.78±0.002 95.01±0.041 88.79 
6 SH1 0.94±0.001 92.49±0.423 79.35 SH6 1.61±0.042 90.62±0.147 87.61 
7 SH2 2.31±0.008 87.08±0.319 80.92 SH7 2.86±0.012 87.47±0.051 88.40 
8 SH3 4.59±0.016 84.75±0.041 86.04 SH8 5.71±0.006 89.83±0.242 90.36 
9 SH4 2.96±0.003 91.62±0.172 87.22 SH9 4.09±0.013 93.45±0.071 88.08 
10 SH5 5.10±0.027 93.38±0.220 84.86 SH10 5.34±0.002 92.08±0.135 87.22 
 
 
Figure 4: Dissolution profiles of Rifapentine, mixtures of Rifapentine and PVP-K30 and solid dispersions prepared 
by kneeding method in 0.1N HCl at 37±0.5°C 
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Figure 5: Dissolution profiles of Rifapentine, mixtures of Rifapentine and HPMC and solid dispersions prepared by 
kneeding method in 0.1N HCl at 37±0.5°C 
 
Figure 6: Dissolution profiles of Rifapentine, mixtures of Rifapentine and PVP-K30 and solid dispersions prepared 
by solvent evaporation method in 0.1N HCl at 37±0.5°C 
 
Figure 7: Dissolution profiles of Rifapentine, mixtures of Rifapentine and HPMC and solid dispersions prepared by 
solvent evaporation method in 0.1N HCl at 37±0.5°C 
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Figure 8: FTIR spectra of Rifapentine bulk drug (A) and SP8 (optimized solid dispersion) (B) 
 
Figure 10: Particle size distribution graph of Rifapentine bulk drug and SP8 (optimized solid dispersion) 
 
Figure 12: DSC graph of Rifapentine bulk drug and SP8 (optimized solid dispersion) 
 
Figure 13: XRD graph of Rifapentine bulk drug and SP8 (optimized solid dispersion) 
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Figure 14: SEM of Rifapentine bulk drug and SP8 (optimized solid dispersion) 
CONCLUSION 
All solid dispersions prepared by kneading method and 
solvent evaporation method shows increment in solubility 
as well as drug release profile as compare to physical 
mixtures with low standard deviation values in percent 
drug content ensured uniformity of drug content in each 
batch. The solubility was enhanced from 0.62 mg/ml (plain 
rifapentine) to 6.34 mg/ml (SP8) by using hydrophilic 
carrier in solid dispersion formulation by using simple 
solvent evaporation technique.  Figure 4 and 6 shows the 
in vitro dissolution profiles of rifapentine from SDs 
containing various ratios of drug to PVP-K30 in which 
max % drug release was obtained in batch SP8 
(93.91±0.22). Figure 5 and 7 shows the in vitro dissolution 
profiles of rifapentine from SDs containing various ratios 
of drug to HPMC in which max % drug release was 
obtained in batch SH8 (90.36±0.22 ). In contrast, the 
dissolution rate of rifapentine from all PVP-K30 and 
HPMC SDs was significantly higher than that of 
rifapentine alone. Physical mixture of PVP-K30 and 
HPMC also improves the dissolution profile of rifapentine 
due to its hydrophilic nature but not such an extent as by 
kneading method and solvent evaporation method. In the 
solid dispersion state because of kneading of rifapentine 
with the polymers, it was converted into amorphous form 
or change in crystal form may changes the different 
physicochemical properties, as per the XRD graph of plane 
drug and solid dispersion proving. The results of scanning 
electron microscopy also show that the changes occurred 
in the morphology and nature of particles from plane drug 
to solid dispersion. The solid dispersion with PVP-K30 
and HPMC have been prepared by different methods in 
different ratios and found that solvent evaporation (SP8) 
shows the better enhancement of solubility in comparison 
to the others. 
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